摘要
目的评价呼吸道感染的4种治疗方案的药物经济学效果。方法采用回顾性研究方法,选择114例呼吸道感染患者,按治疗方案分为4组(A,B,C,D组),分别观察其疗效并运用成本-效果分析法(CEA)进行分析。结果4组治疗方案成本分别为190.40,403.20,1380.96,174.72元,临床有效率分别为86.7%,86.7%,90.0%,62.5%,成本-效果比(C/E)分别为2.19,4.65,15.34,2.79,A,B,C组相对于D组的增量成本-效果比(ΔC/ΔE)分别为0.65,9.44,43.86。结论A组(头孢曲松组方案)为最佳的治疗方案。
Objective To evaluate the pharmacoeconomic effectiveness of the four therapeutic schemes for respiratoy tract infections. Methods A retrospective study was conducted, in which a total of 114 cases with respiratory tract infection were enrolled and randomly assigned to receive each of the following 4 therapies （group A, B, C, D）. The therapeutic effects were monitored and the cost-effectiveness analysis was adopted on the four treatment schemes. Results The costs of the four regimens were 190. 40 yuan, 403.20 yuan, 1 380. 96 yuan and 174. 72 yuan. The clinical effective rates were 86. 7%, 86. 7%, 90. 0% and 62. 5% ,respectively. The cost - effectiveness rates （ C/ E） were 2. 19, 4. 65, 15.34 and 2. 79,respectively. And the incremental cost - effectiveness rates （/△ C/△ E） of group A, B and C were 0. 65, 9.44 and 43.86 respectively, as against group D. Conclusion Group A （ceftriaxone treatment group） is the best therapeutic scheme.
出处
《中国药业》
CAS
2007年第8期45-46,共2页
China Pharmaceuticals
关键词
呼吸道感染
治疗方案
药物经济学
成本-效果分析
respiratory tract infection
therapeutic scheme
pharmacoeconomics
cost - effectiveness analysis
